BackHeat Biologics Overview

Heat Biologics Receivables

Latest receivables for HTBX: $180B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$179.89B

Peer average

Loading

Heat Biologics Receivables History

Loading

Heat Biologics vs. peers: Receivables Comparison

Loading

Heat Biologics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Heat Biologics (HTBX) FAQ

Heat Biologics (HTBX) currently reports a receivables of $180B as of September 2025. Use the charts on this page to explore Heat Biologics's receivables history and peer comparisons.

Heat Biologics reported $180B in receivables as of September 2025. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $180B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Heat Biologics, and consider following HTBX for alerts when major investors trade the stock.

Heat Biologics is classified in the Healthcare sector. On receivables, it currently shows $180B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HTBX with unrelated industries.